Boston Oncology Arabia’s pharmaceutical manufacturing facility in Sudair Industrial City.
Boston Oncology Arabia has received Good Manufacturing Practice (GMP) certification from the Saudi Food and Drug Authority (SFDA) for its pharmaceutical manufacturing facility in Sudair Industrial City.
The certification confirms that the facility meets the applicable Saudi regulatory requirements for pharmaceutical manufacturing and marks an important operational milestone in the continued development of Boston Oncology Arabia’s integrated local platform.
Purpose-built to support the production of complex biosimilars, injectable therapies, and peptides, the facility brings together flexible manufacturing, robotic closed-isolator filling systems, analytical testing laboratories, and integrated warehousing within one operating environment.
With SFDA GMP certification in place, Boston Oncology Arabia is positioned to expand localized development and manufacturing, support technology transfer, and deepen collaboration with pharmaceutical partners seeking an established operating base in Saudi Arabia.
The milestone also advances the company’s contribution to Saudi Vision 2030—strengthening national pharmaceutical capability, supporting medicine security, and expanding the Kingdom’s capacity for technology-driven pharmaceutical production.
Related Links
Explore Our Manufacturing Capabilities
